Assessing the ocular risks from GLP-1s

In an exclusive interview with Optometry Times, Jessica Steen, OD, FAAO, DipABO, discussed the evolving understanding of GLP-1 receptor agonists, highlighting their profound systemic benefits while acknowledging emerging but still uncertain ocular safety signals. She began by emphasizing that these agents are genuinely “game-changing” in the management of cardiovascular disease, diabetes, and obesity. This overarching benefit profile serves as the essential context for any risk–benefit analysis, including concerns about potential eye-related adverse events.

A central theme is the ongoing refinement of data around GLP-1–associated ocular risks, particularly non-arteritic anterior ischemic optic neuropathy (NAION). Steen referenceed a recent publication suggesting that the NAION risk may actually be lower than earlier reports implied. However, the mechanism by which GLP-1 receptor agonists might influence ocular health remains unclear. It is unknown whether any observed effect is direct or instead mediated through broader physiological changes induced by these agents—such as alterations in vascular, metabolic, or hemodynamic parameters. This mechanistic uncertainty complicates efforts to ascribe a definitive cause-and-effect relationship.

Given these gaps in understanding, Steen argued for a balanced, “big picture” perspective. From a holistic, systemic standpoint, the benefits of GLP-1 receptor agonists for most patients—improvements in cardiovascular outcomes, glycemic control, and weight—generally outweigh what appears to be a low but still noteworthy potential ocular risk. Rather than prompting indiscriminate alarm, the current evidence supports heightened awareness and thoughtful monitoring.

Steen also stressed the importance of transparent communication between patients and eye-care providers. Comprehensive assessment depends on patients feeling comfortable disclosing their full medical history, including all medications. The speaker acknowledges that some individuals may be reluctant to share certain treatments, but underscores that, when complications occur, targeted questioning about specific agents becomes crucial.

Finally, Steen provides pragmatic guidance: any patient who perceives a change in vision should seek prompt evaluation and not wait to see whether symptoms resolve spontaneously, regardless of which systemic medications they are taking. Urgent or emergent assessment by an optometrist or eye-care professional is framed as a critical safeguard. Overall, the message is one of measured vigilance—respecting the transformative systemic advantages of GLP-1 therapies while remaining alert to, and prepared to investigate, possible ocular side effects.